FDA drug class
CTLA-4-directed Blocking Antibodies list
Every FDA-approved prescription drug the FDA NDC directory tags with the CTLA-4-directed Blocking Antibody [EPC] class, with brand names and DEA schedules.
Source: FDA NDC Directory file dated 2026-10-22. Publisher page
The FDA NDC directory lists 2 single-ingredient drugs in this class: ipilimumab, tremelimumab.
Run it in Rivvi
Map Yervoy and your other top fills to their generics
Every strength in RxNorm, with brands that have no generic flagged.
Build the mapFree to start. Opens Rivvi, the AI workspace for healthcare teams.
CTLA-4-directed Blocking Antibodies (2)
| Drug | Brand names | Type | NDC listings | DEA schedule |
|---|---|---|---|---|
| Ipilimumab | Yervoy | Single ingredient | 2 | Not controlled |
| Tremelimumab | Imjudo | Single ingredient | 2 | Not controlled |
FDA established pharmacologic class: CTLA-4-directed Blocking Antibody [EPC].
Questions
What drugs are CTLA-4-directed Blocking Antibodies?
The FDA NDC directory lists 2 single-ingredient drugs in this class: ipilimumab, tremelimumab.
Where does this list come from?
From the established pharmacologic class (EPC) field FDA publishes for each listing in the NDC directory. A drug is listed when most of its prescription listings carry the class.